Fusion protein · developed by Nektar Therapeutics
Rezpegaldesleukin is an injectable subcutaneous drug studied in moderate-to-severe atopic dermatitis and systemic lupus erythematosus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07711418 | Phase 3 | Moderate-to-Severe Atopic Dermatitis | Recruiting | NKTR |
| NCT04433585 | Phase 2 | Systemic Lupus Erythematosus | Completed | NKTR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Moderate-to-Severe Atopic DermatitisSystemic Lupus Erythematosus
Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.
See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NKTR catalysts and pipeline →